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The spectrum of mixed brain pathologies expands beyond accompanying vascular pathology in brains with
Alzheimer’s disease-related pathology. Co-occurrence of neurodegenerative non-Alzheimer’s disease-type
proteinopathies is increasingly recognized to be a frequent event in the brains of symptomatic and asymptomatic
patients, particularly in older people. Owing to the evolving concept of neurodegenerative diseases, clinical and
neuropathological diagnostic criteria have changed during the last decades. Autopsy-based studies differ in the
selection criteria and also in the applied staining methods used. The present review summarizes the prevalence of
mixed brain pathologies reported in recent community-based studies. In these cohorts, irrespective of the clinical
symptoms, the frequency of Alzheimer’s disease-related pathology is between 19 and 67%, of Lewy body pathology
is between 6 and 39%, of vascular pathologies is between 28 and 70%, of TDP-43 proteinopathy is between 13 and
46%, of hippocampal sclerosis is between 3 and 13% and, finally, of mixed pathologies is between 10 and 74%.
Some studies also mention tauopathies. White-matter pathologies are not discussed specifically in all studies,
although these lesions may be present in more than 80% of the aging brains. In summary, community-based
neuropathology studies have shown that complex constellations of underlying pathologies may lead to cognitive
decline, and that the number of possible combinations increases in the aging brain. These observations have
implications for the prediction of the prognosis, for the development of biomarkers or therapy targets, or for the
stratification of patient cohorts for genome-wide studies or, eventually, for therapy trials.Introduction: definition of neurodegenerative
diseases and mixed pathologies
Owing to increased life expectancy, understanding the
pathogenesis of age-associated cognitive decline is becom-
ing more and more important [1]. There are many causes
of dementia, but neurodegenerative diseases (NDDs) are
thought to be one of the most prevalent in the aging
population. Indeed, during the last century neuropatho-
logical examinations, based mostly on silver stainings,
have demonstrated that the brains of the majority of the
individuals with cognitive decline show Alzheimer’s dis-
ease (AD)-related pathologies, including neurofibrillary
tangles and senile plaques. This observation led to the
concept that AD is the most frequent NDD and cause of
cognitive decline in older people.
NDDs are traditionally characterized by a selective loss
of neurons in distinctive anatomical regions correlating* Correspondence: gabor.kovacs@meduniwien.ac.at
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unless otherwise stated.with the predominant clinical manifestations. In addition,
intracellular or extracellular deposition of misfolded pro-
teins can be observed, resulting in the protein-based clas-
sification (proteinopathies) of these disorders [2,3]. For
instance, amyloid beta (Aβ) and abnormal conformers of
the prion protein are found as extracellular deposits and
also in vessels in the form of cerebral amyloid angiopathy
(CAA). The intracellular microtubule-associated protein
tau can deposit in neurons or glial cells. Neuronal tau de-
position is an important feature of frontotemporal lobar
degeneration (FTLD) with Pick bodies. Progressive supra-
nuclear palsy (PSP), corticobasal degeneration, and argyro-
philic grain disease (AGD) show both neuronal and glial
tau aggregates [3]. On the contrary, globular glial tauopa-
thies show inclusions predominantly in glial cells [4].
There are further tau pathologies, including tangle-
predominant dementia or various astrogliopathies, which
have been described in the brains of older individuals
[5,6]. Aggregates of pathologic α-synuclein are found ei-
ther in the form of neuronal Lewy bodies or as Lewy neur-
ites in disorders with Lewy bodies [2]. These compriseentral Ltd. The licensee has exclusive rights to distribute this article, in any
ion. After this time, the article is available under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Overview of the community-based studies
discussed in the present review
Study Country
Rush Memory and Aging Project USA
Religious Orders Study USA
Medical Research Council Cognitive Function and Ageing Study UK
Cambridge City Over-75 s Cohort UK
Vantaa 85+ Finland
Hisayama Japan
Honolulu–Asia Aging Study USA
Adult Changes in Thought USA
Baltimore Longitudinal Study of Ageing USA
Oregon Brain Aging Study USA
90+ Study USA
Vienna Trans-Danube Aging study Austria
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Synuclein-positive glial cytoplasmic inclusions (Papp-Lantos
bodies) characterize multiple system atrophy. Only in re-
cent years was Tar-DNA binding protein 43 (TDP-43), a
widely expressed nuclear protein, recognized as the major
protein in cases of FTLD with ubiquitin-immunoreactive
inclusions with or without motor neuron disease and in
sporadic motor neuron disease or amyotrophic lateral
sclerosis [7]. Other relevant proteins in FTLDs are the
so-called FET proteins, including the fused in sarcoma
protein, Ewing’s sarcoma, and TATA-binding protein-
associated factor 15 [8].
Owing to the evolving concept of NDDs, diagnostic
criteria have also changed during the last decades. For
instance, the Consortium to Establish a Registry for AD
(CERAD) criteria were used in most of the neuropathology-
based studies of AD [9]; however, these focus only on the
presence of neuritic plaques (NPs). Staging for neurofibril-
lary tangles (NFTs) proposed by Braak, first in 1991 using
silver staining and later in 2006 using immunohistochem-
istry for phospho-tau (AT8) [10,11], was later also recog-
nized as an important diagnostic hallmark, and hence was
reflected in the National Institute on Aging (NIA)–Reagan
1997 criteria [12]. In 2002 Thal and colleagues published
that Aβ deposition also follows a hierarchical pattern in
the brain [13], a concept that was implemented in the re-
cent NIA–Alzheimer’s Association (AA) 2012 criteria
[14,15]. For the neuropathological diagnosis of disorders
with Lewy bodies, two different sets of criteria or staging,
although partly overlapping, have been proposed. The
2003 scheme of Braak and colleagues suggested a hier-
archical distribution in six stages [16]. On the contrary,
the Consensus criteria on dementia with Lewy bodies
distinguished three main categories. These criteria were
first developed in 1996 and later revised [17-19]. In
addition, cases where Lewy bodies were mainly restricted
to the amygdala were included separately as an amygdala-
predominant type of α-synucleinopathy [20,21].
Co-occurrence of neurodegenerative pathologies (includ-
ing non-AD forms and other proteinopathies) and nonde-
generative pathologies (vascular, metabolic–nutritional,
and so forth) is increasingly recognized to be a frequent
event in the brains of symptomatic and asymptomatic pa-
tients [5,22-24], which may be an explanation for the often
complex clinical presentations. In addition, hippocampal
sclerosis (HS), defined as neuronal loss and gliosis in the
hippocampal formation that is out of proportion for
AD-type pathology, is a frequent finding in demented
patients – and is particularly associated with AD and
TDP-43 pathology [25]. In sum, the term mixed or con-
comitant pathology can be defined as the observation of
further pathological changes in addition to predominant
lesions of an NDD entity, including AD or other, in the
same brain [24]. In earlier studies, this term was usedfor the assessment of accompanying vascular pathology
in brains with AD-related pathology. Later, Lewy body
pathology was also considered a concomitant pathology.
This definition must be expanded, however, and thus we
use the term mixed pathology to indicate the concomi-
tant presence of any neurodegenerative proteinopathy
and/or further pathologic alterations, including HS, vas-
cular lesions, or other pathologies.
Autopsy-based studies differ in the selection criteria
and also in the applied staining methods and neuro-
pathological criteria used. Comprehensive studies (that
is, brain bank, community-based or other autopsy co-
horts) that include the examination of different NDD-
related proteins were reported only in the last few years.
The aim of the present review is to summarize and to
compare the prevalence of mixed pathologies reported
in recent community-based studies. The following stud-
ies are discussed in the present review (most of them are
reported in several publications): Rush Memory and
Aging Project (USA), Religious Orders Study (USA),
Medical Research Council Cognitive Function and Age-
ing Study (UK), Cambridge City Over-75 s Cohort (UK),
Vantaaa 85+ (Finland), Hisayama (Japan), Honolulu–Asia
Aging Study (USA, Japanese–American), Adult Changes
in Thought (USA), Baltimore Longitudinal Study of Age-
ing (USA), Oregon Brain Aging Study (USA), 90+ Study
(The Leisure World Retirement Community, USA), and
Vienna Trans-Danube Aging (VITA) study (Austria) (see
also Table 1). These community-based studies imple-
ment more recent neuropathological diagnostic criteria
or staging systems and include the evaluation of α-
synucleinopathy, tau pathologies, and TDP-43. Although
the definition of community- or population-based studies
varies, generally a community is designated as a group of
people living in a defined geographic area but being demo-
graphically and socioeconomically diverse [26].
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compare them with recent noncommunity-based stud-
ies, including those that implemented the proteinopathy
concept in their evaluation process. Importantly, compari-
son of community cohorts versus clinic-based cohorts has
shown that more atypical pathologies are found in the lat-
ter and hence generalization of these findings to the gen-
eral population may be problematic [27].
Differences in the methodological approach of
neuropathology-based studies
The age of the participants included in the projects at
baseline evaluation is crucial for the estimation of the
prevalence of mixed pathologies, since younger patients
tend to have only single neurodegenerative pathologies
in contrast to older patients, where mixed pathologies
very often contribute to their degree of cognitive decline
[28,29]. A further aspect of understanding the differ-
ences in the frequency of neuropathological alterations
in community-based studies is related to the fact that
these use different criteria and methods (summarized in
Table 2).
All studies used the CERAD criteria and staging of
neurofibrillary degeneration according to Braak and
Braak [9,10] to assess AD-related pathology. However,
only nine out of 12 studies also used immunohistochem-
istry for phospho-tau (Table 2). Indeed, a study by the
BrainNet Europe Consortium has demonstrated that
the quality of silver stainings varies considerably even
in the same laboratory, which makes reproducibilityTable 2 Summary of methodological approaches used in the
in this review
Study n Neuropathological criteria
BB C NR NA DLB/Br
MAP [27,30-33] 425 + + + +a
ROS [27,30,32-35] 539 + + + +a
MRC CFAS [21,36-39] 525 + + +a,c
CC75C + [40] 224 + + +a
Vantaa 85 + d [41-43] 304 + + +a
Hisayama [44,45] 205 + + +e
HAAS [46-48] 439 + + +e
ACT [49,50] 438 + + + +e
BALS [51,52] 209 + + +e
OBASd [53,54] 125 + + + +e
90+ Studyd [55] 108 + + +e
VITA [5] 233 + + + + +c
Aβ, amyloid beta; ACT, Adult Changes in Thought; α-Syn, α-synuclein; BALS, Baltimo
disease; Br, Braak; C, Consortium to Establish a Registry for AD criteria; CC75C, Camb
bodies; HAAS, Honolulu–Asia Aging Study; HS, hippocampal sclerosis; MAP, Rush M
Function and Ageing Study; n, number of individuals included in the studies; NA, N
on Aging–Reagan criteria; OBAS, Oregon Brain Aging Study; ROS, Religious Orders Stud
Aging study. aDLB criteria 1996. bNot assessed in all participants. cBraak staging for Parand comparability of this method very difficult [56,57].
In contrast, immunohistochemistry for phospho-tau, par-
ticularly AT8, shows uniform results [56]. Moreover, im-
munohistochemistry is useful in detecting neuronal and
glial pathologies additional to NFTs and NPs. This tech-
nique therefore facilitates the recognition of other NDDs,
such as AGD, PSP, corticobasal degeneration, or less fre-
quent tauopathies. NIA–Reagan criteria (which combine
CERAD criteria and Braak and Braak staging) for the diag-
nosis of AD [12] have been applied in 6/12 studies, while
the NIA–AA criteria [14,15] were used only in a single
study (Table 2).
Depending on the date of the study and the version of
the dementia with Lewy bodies Consortium diagnostic
criteria [17,18], the detection of Lewy bodies varied; in
particular, not all studies used immunostaining for α-
synuclein (Table 2). Although amygdala-predominant
Lewy body pathology frequently associates with AD [58],
only two studies commented specifically on its frequency
(Table 3). The importance of TDP-43-related pathology
has emerged in recent years, and hence only three stud-
ies screened for this protein (Table 2). All investigators,
except those from two studies [44,51], mentioned that
they screened for HS. Again, definition of HS and dis-
tinction from hippocampal microinfarction is particu-
larly important [59].
Vascular pathologies, including CAA, were evaluated
in all studies. Macroscopic and microscopic lesions were
identified in all studies, but some reported more exten-
sively on the impact of these lesions and their relation tocommunity-based neuropathological studies summarized
Aβ Tau α-Syn Ubi/p62 TDP-43 Vascular
pathologies
HS
+ + + + +
+ + + +b + +
+ + + + + +
+ + + + + +
+ + + + + +
+ + + +
+ + + +
+ + +
+ +
+ + + +
+ + + + + +
+ + + + + + +
re Longitudinal Study of Ageing; BB, Braak and Braak staging for Alzheimer’s
ridge City Over-75 s Cohort; DLB, McKeith criteria for dementia with Lewy
emory and Aging Project; MRC CFAS, Medical Research Council Cognitive
ational Institute on Aging–Alzheimer’s Association criteria; NR, National Institute
y; TDP-43,Tar-DNA binding protein 43; Ubi, ubiquitin; VITA, Vienna Trans-Danube
kinson’s disease. dAge of autopsied cohort >90 years. eDLB criteria 2005.
Table 3 Frequency of different neuropathological variables in community-based studies




Braak III to VI CERAD NIA
MAP [27,30] 59% (195) 15% (195) 13% (100) 46%a (195) 23% (195)
ROS [27,30,35] 61% (386) 21% (386) 46% (130) 13% (100) 49%a (386) 28% (386)
MRC CFAS [21,37] 52% (456) 46% (456) 39% (29% amygdala) (208) 70%b (456)
CC75C [40] 39%c (213) 28% (213) 15% (213) 56%d (213)
Vantaa 85+ [41-43] 70% (304) 66% (180) 41%e (180) 36% (304) 5% (132) 55%a (132) 40% (132)
Hisayamaf [44,45] 62% (205) 29% (205) 31% (29) 10%g (29)
HAAS [48] 19%h (363) 10%f (363) 9%f (363) 28%d (363) 39.5% (363)
ACT [49] 62% (438) 47% (438) 14% (438) 35%d (438)
BALS [51,52] 56%i (209) 6%f (34) 44%a (179)
OBAS [53] 62% (71) 44% (71) 20% (71) 7% (71) 46%d (71)
90+ Study [55] 67% (108) 6%j (108) 31% (108) 29%f (66) 19%k (108)
VITA [5] 38% (233) 35% (233) 25% (17.2% amygdala) (233) 13% (233) 3% (233) 49%l (233) 74% (233)
AD-related pathology according to CERAD was defined as moderate and frequent neuritic plaques. Using NIA–Reagan criteria, intermediate and high likelihood
probabilities were included as AD-related pathology. Mixed pathologies were usually defined as AD plus any other pathology, if not further specified. Values in
parentheses refer to the total number of brains autopsied and evaluated for pathologies in the referred study. ACT, Adult Changes in Thought; AD, Alzheimer’s
disease; α-Syn, α-synuclein; BALS, Baltimore Longitudinal Study of Ageing; CC75C, Cambridge City Over-75 s Cohort; CERAD, Consortium to Establish a Registry for
AD criteria; DLB, McKeith criteria for dementia with Lewy bodies; HAAS, Honolulu–Asia Aging Study; HS, hippocampal sclerosis; MAP, Rush Memory and Aging
Project; MRC CFAS, Medical Research Council Cognitive Function and Ageing Study; NIA, National Institute on Aging; OBAS, Oregon Brain Aging Study; ROS,
Religious Orders Study; TDP-43,Tar-DNA binding protein 43; VITA, Vienna Trans-Danube Aging study. aMacroscopic and microscopic infarcts/brain infarcts. bAny
vascular disease. cSevere hippocampal neurofibrillary tangles. dMicroinfarcts/cortical microvascular lesions. eBraak stages IV to VI with moderate or frequent neuritic
plaques. fData only reported for demented subjects. gAD + vascular disease. hPure AD cases defined as frequent neuritic plaques according to CERAD or Braak
stages V and VI. iComposite AD pathology score by summing CERAD and Braak in equal measures (score >4 included). jDLB high likelihood. kAD+DLB/frontotemporal
dementia. lVascular pathology including bleeding and ischemic lesions.
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pretation of vascular pathology in terms of cognitive de-
cline is problematic, since there are no clear guidelines
regarding assessment and relevance of these lesions [65].
The recent NIA–AA consensus guidelines provide sug-
gestions about neuropathological characterization of
vascular changes and emphasize that the number of le-
sions is very important [15].
Frequency of neurodegenerative conditions in the
aging brain
The frequencies of NDDs in different community-based
studies are shown in Table 3 and Figure 1. AD-related
pathology is the most frequent irrespective of the cogni-
tive status of the individuals included in the study, even
when moderately or highly advanced stages or scores are
taken into account (that is, Braak stage ≥3; CERAD
scores B and C; and NIA–Reagan and NIA–AA criteria
intermediate or high likelihood) (Figure 1A). Statistical
comparison of the reported values (analysis of variance,
analysis of variance with Tukey’s post hoc test) shows
that, for the studies included in the present review, the
frequency of AD-related pathology (range 19 to 67%) is
not significantly greater than that for vascular pathology
(range 28 to 70%) or mixed pathologies (range 10 to
74%). On the contrary, only HS (range 3 to 13%) is re-
ported as significantly less frequent than other pathologies(P <0.05). However, AD-related pathology mostly associ-
ates with cognitive decline (Figure 1B), supporting the no-
tion that isocortical NFTs and NPs contribute mostly to
dementia [66-68]. Findings from the Nun study identified
NFT pathology as a major contributor to cognitive impair-
ment, but the study also indicates that additional factors
such as brain reserve or age contributes to the variants ob-
served in cognitive decline [68].
The second most common neurodegenerative disorder
is described as Lewy body pathology (range 6 to 39%).
The evaluation of Lewy body-related pathology depends
strongly on the methodology and on the regions assessed.
Some studies focused on limbic and neocortical Lewy
bodies; indeed, neocortical Lewy bodies are mainly associ-
ated with cognitive decline [34,66,69]. However, it has
been suggested that so-called incidental Lewy body disease
(brainstem) is already presymptomatic Parkinson’s disease
[70], and thus the presence of Lewy bodies most probably
contributes to additional symptoms and possibly also to
the prognosis. Supporting this concept, evidence for a re-
lationship between Lewy bodies in the substantia nigra
and functional disability has been reported in nondemen-
ted older people [71].
Although the prevalence of HS is low in the general
population (Table 3), it is twice as frequent in a demen-
ted cohort (Figure 1B) [55]. The distribution of TDP-43
pathology varies remarkably (range 13 to 46%), partly
Figure 1 Frequencies of different brain pathologies reported in the studies discussed in the present review. Box-plot representation of
brain pathology frequencies (A) for all study subjects pooled together and (B) separately for individuals with or without (that is, with no) cognitive
impairment (CI). AD defined as the frequency of AD-related pathology starting from Braak and Braak stages III to VI or National Institute on Aging–
Reagan criteria intermediate or high likelihood, ignoring other pathologies. Mixed pathologies defined as AD plus any other pathology (see also
Table 2). AD, Alzheimer’s disease; aSyn, α-synuclein; HS, hippocampal sclerosis; n, number of studies that report any values; TDP, TDP-43 proteinopathy;
Vasc, vascular pathology.
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due to how the presence of TDP-43 immunoreactivity is
specified [35]. Furthermore, less common NDDs – such
as multiple system atrophy, PSP, corticobasal degener-
ation, tangle-predominant dementia, FTLD-TDP [72]
and even Pick bodies – are also reported in a subset of
their subjects (usually below 5 to 10%) [5,27,36,41,45,51].
Application of phospho-tau immunostaining in several
anatomical regions allowed the VITA study to identify a
spectrum of further tau pathologies associated with the
aging brain, including their association with cognitive
decline [5,6]. These pathologies expand beyond the fre-
quently detectable thorny astrocytes in the medial tem-
poral lobe including periventricular locations [73].
Similarly to the VITA study, the brain bank-based
Arizona Study of Aging and Neurodegenerative Disor-
ders also emphasized that PSP pathology is more com-
mon in the general population than thought and that its
clinical presentation varies in relation to concomitant
pathologies [5,74]. All together, these observations call
for caution in the interpretation of frequencies when
only a few methodologies are applied (for example, silver
stainings) and only restricted anatomical regions are
sampled or evaluated.
Frequency of vascular pathologies in the aging
brain
Vascular pathologies are also reported as being frequent;
however, due to the lack of clearly defined assessment
criteria [65] there is a large range of values (Figure 1), asreported also in large autopsy cohorts [75]. Among pa-
tients with low AD-related pathology and cognitive im-
pairment, brain infarctions were reported to be the most
frequent concomitant pathology responsible for their
symptoms [52,60-64,76]. The spectrum of vascular path-
ologies assessed at autopsy ranges from large macro-
scopic and smaller microscopic infarcts and lacunar
infarcts, to hemorrhages, to small vessel disease and CAA.
For simplification and comparability, we only present an
overview of the prevalence of brain infarctions in Table 3.
Multiple lacunar infarctions were reported by the
Hisayama study to be the most frequent finding in cases
with dementia with a prevalence of 42% [60]. The same
study reported that vascular dementia is more frequent
in the Japanese population than in the western popula-
tion, while the general prevalence of dementia is com-
parable [60]. On the contrary, the VITA study showed in
the total cohort (including demented and nondemented
individuals) that single micro and territorial infarcts are
found frequently (up to 33%) [5]. Several studies discuss
that the presence of multiple infarctions is more relevant
regarding cognitive decline than the size of single infarcts
[52,62,64]. While the Baltimore Longitudinal Study of
Ageing suggests that only hemispheral infarcts have a
strong effect, the Medical Research Council Cognitive
Function and Ageing Study emphasizes that subcortical
infarcts also have an influence on cognitive impairment
[37,52]. The Baltimore Longitudinal Study of Ageing
specifically comments on this controversy, explaining
that they included subcortical infarctions also in their
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was that minor vascular lesions hardly contribute to
cognitive decline in full-blown AD, while both mild
AD-related pathology and small vessel disease interact
synergistically [77]. Moreover, the lesion pattern in
mixed dementia (that is, defined as AD plus vascular
encephalopathy) is often associated with large infarcts,
instead of with microangiopathy as in pure vascular
dementia/vascular cognitive disorder [77].
Regarding the prevalence of vascular pathologies in
the studies discussed here (Table 3), prevention and
treatment of comorbidities such as hypertension, dia-
betes, alcohol consumption and previous stroke could
ameliorate cognitive decline in a considerable fraction of
patients [61,75,76]. Indeed, a recent population-based
study also emphasized that the lack of appropriate con-
trol of risk factors for circulatory diseases combined with
genetic particularities might relate to the high prevalence
of vascular pathologies [78].
CAA is a frequent finding in the aging brain, being
more frequent in demented people [79]. CAA is not only
associated with the development of AD, but is also a
highly relevant cause for hemorrhage and brain infarc-
tion [79,80]. Furthermore, CAA can be a risk factor for
cognitive decline without significant AD pathology in
older people [75]. The VITA study distinguished the two
types of CAA as proposed by Thal and colleagues [81],
and reports a significant association between higher
CERAD scores, higher phase of Aβ deposition, and
higher Braak stages. Furthermore, the study also found
that the capillary type of CAA was related to hippocam-
pal infarctions [5].
White-matter pathologies including periventricular
and subcortical lesions are not discussed specifically in
all studies. These lesions have a complex pathological
basis and etiology, and may be present in more than
80% of the aging brains, somewhat (but not significantly)
more in the demented [63]. Furthermore, white-matter
hyperintensities, detectable on T2 and fluid-attenuated
inversion recovery brain magnetic resonance imaging
(MRI), are found in similar frequencies in older cohorts.
Some studies suggested that these white-matter hyperin-
tensities detected by MRI are related to CAA, but this
was not confirmed in the Vantaa 85+ Study, which eval-
uated white-matter hyperintensities by postmortem MRI
and neuropathologically assessed CAA in demented and
nondemented subjects. However, this study also showed
a high frequency of these alterations detectable in the
postmortem MRI scans (74% in the total cohort) [82]. A
longitudinal MRI study in individuals with advanced age
suggested that accumulating white-matter changes in ad-
vanced age are probably driven by small-vessel ischemic
disease, and even suggested there might be a link between
AD pathology and white-matter integrity disruption [83].Regarding their relevance on cognition, white-matter
pathologies are controversially discussed. It has been
suggested that radiologists tend to overreport periven-
tricular and perivascular brain lesions in the MRI T2/
fluid-attenuated inversion recovery compared with histo-
logically evaluated demyelination [84]. On the contrary,
routine histological assessment may underrate subcor-
tical vascular pathology; hence, application of postmor-
tem MRI was recommended as a complementary tool
for the detection of these lesions [85].
Frequency of mixed pathologies: high number of
possible combinations
Depending on the definition of mixed pathologies –
from AD plus vascular pathology to AD plus any path-
ology – the prevalence lies between 10 and 74%, with a
higher prevalence in demented patients (Table 3 and
Figure 1). Thus, although AD has been regarded as the
most common cause of dementia in older people, the
prevalence of mixed pathologies is on average at least as
frequent. Mixed pathologies increase the odds of dementia
up to almost 10 times, and up to three times compared
with patients with only one pathology [86]. Moreover, the
higher the Braak and Braak stage of neurofibrillary degen-
eration and the amount of NPs, the more probable the
presence of further pathological alterations [5]. The rate of
neuropathologically confirmed intermediate- and high-
likelihood AD plus any other second pathology was
reported as up to almost 54% in a subset of the Rush
Memory and Aging Project cohort [86]. In the VITA
study, where mixed pathologies were defined as any other
pathologies, including also less regarded pathologies such
as HS and TDP-43 proteinopathy, and non-AD tauopa-
thies, the prevalence of mixed pathologies was over 70%
[5]. Similarly to these, the Honolulu–Asia Aging Study
also concluded that the co-occurrence of combined path-
ologies contributes to the severity of dementia and that
the frequency of these pathologies increases with age [87].
The high prevalence of mixed pathologies confirmed by
autopsy supports the theory that a combination of neuro-
pathological alterations often has a cumulating effect,
and – if reaching the individual’s threshold for cognitive
impairment – manifests as clinical dementia [5,38].
In addition to the studies included in the present review,
further autopsy-based studies that used different recruit-
ment and neuropathological methods also concluded that
mixed pathologies are frequent and show particular in-
crease with age [22,23,29,88]. Further studies support the
concept that to understand the spectrum of pathologies in
older people, non-AD type pathologies should also be eval-
uated in detail [25,74]. When discussing the prevalence of
mixed pathologies, not only the pure frequency values are
important, but also that the number of the combinations
of major alterations can be very high (Figure 2) [5].
Figure 2 Summary of the concept of mixed pathologies. The holistic approach suggests that the number of combinations of different
neuropathological substrates might be very high. Different combinations are covered by the umbrella term mixed pathologies. Aβ, amyloid beta;
AD, Alzheimer’s disease; ALB, amygdala predominant Lewy body pathology; AGD, argyrophilic grain disease; CAA, cerebral amyloid angiopathy;
CBD, corticobasal degeneration; MSA, multiple system atrophy; PSP, progressive supranuclear palsy; TDP-43, TAR DNA-binding protein 43; TPD,
tangle-predominant dementia.
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Most of the studies agree that NFTs, NPs, neocortical
Lewy bodies and cerebral infarctions associate with age-
related cognitive decline. We compared the frequency
values of pathological variables in cases with and without
cognitive impairment reported in the studies discussed in
the present review using the Mann–Whitney test. This
comparison shows that AD-related and Lewy body path-
ologies and HS are significantly (P <0.05) more frequent in
individuals with cognitive decline. Regarding mixed and
vascular pathologies and TDP-43 proteinopathy, the com-
parison did not reveal significant differences; however, this
might also be due to differences in the definitions (that is
mixed and vascular pathologies) or in the number of studies
reporting on these values (that is, TDP-43 proteinopathy).
The contribution of vascular lesions to clinical demen-
tia still remains a matter of debate. While some studies
state that vascular pathologies directly contribute to de-
mentia depending on their frequency and localization
[87], others consider also a cumulative effect of this en-
tity with co-existing NDD in the same brain [46]. In-
deed, the Nun study observed that patients withoutlacunar infarctions seem to tolerate more AD-related
pathology before presenting with dementia [89]. Further-
more, less frequent pathological changes that are highly
related to dementia should not be disregarded, since
they are sometimes quite challenging regarding the clin-
ical classification of dementia [67].
The assessment of TDP-43 pathology is becoming in-
creasingly important, since these protein aggregations are
not only related to HS and FTLD-TDP, but are also associ-
ated with AD-related pathology [35]. A recent study em-
phasized that TDP-43 pathology is more frequent in HS
compared with typical or limbic predominant AD and also
shows a different distribution pattern [90]. This pathology
can even expand beyond the medial temporal lobe loca-
tion and be widespread, especially when associated with
complex tauopathies [6]. TDP-43-related pathology and
HS are two findings often observed together [25,91]. Al-
though their frequency usually lies below 15% in the aut-
opsy cohorts, it is noteworthy that the prevalence of HS
increases above 20% in demented patients [5,55,67]. Per-
sons with HS had lower final Mini-Mental State Examin-
ation scores [66]. HS cases were significantly older at
Note: This article is part of a series on Cerebral multi-morbidity
of the aging brain edited by Johannes Attems and Julie
Schneider. Other articles in the series can be found at
http://alzres.com/series/cerebral_multimorbidity
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AD subtypes [90]. Association of TDP-43 pathology with
or without HS with cognitive decline or with more rapid
progression of the impairment was shown in different
studies [5,25,35,55,66,91]. A recent study suggests that
TDP-43 is indeed a key player in the clinical features asso-
ciated with AD [92]. On the contrary, one must note that
some observations indicate that deposition of TDP-43 oc-
curs in a substantial subset of cognitively normal older
subjects [93].
Interestingly, an association of argyrophilic grains (tau
pathology) with cognitive impairment could not be con-
firmed [66]. AGD can still be considered as a component
that lowers the threshold for cognitive decline. On the
contrary, non-AD tauopathies have an effect on the cogni-
tive decline or may associate with further neurological
symptoms leading to disability [5,74]. A combined analysis
of the Rush Memory and Aging Project and the Religious
Orders Study results showed that only 41% of the variance
in cognitive decline can be explained by the commonly ex-
amined pathologies (AD, vascular lesions, dementia with
Lewy bodies), suggesting that further causes – such as
TDP-43 aggregation, HS or inflammation – should be con-
sidered in neuropathological evaluation to obtain represen-
tative explanations for cognitive alterations in aging [94].
Conclusions and perspectives
Community-based neuropathology studies have shown
that complex constellations of underlying pathologies may
lead to cognitive decline, and that the number of possible
combinations increases in the aging brain. However, cau-
tion is needed for the interpretation of frequency values,
since the methods and criteria used and the brain regions
assessed are different. Nevertheless, for clinicians these
findings may be an explanation of why the diagnosis, treat-
ment, or prediction of the prognosis can be challenging.
The development of biomarkers may be a helpful tool in
evaluating causes of dementia. However, one has to be
aware that concomitant pathologies can bias the results of
these tests. An increase of tau in the cerebrospinal fluid,
for instance, can also result from disorders other than AD
[28]. Furthermore, we do not know how other co-existing
proteinopathies influence biomarkers and whether they
can be measured via some tests in future [28]. In addition,
for example, HS is clinically difficult to distinguish from
AD since it not only results in memory loss but is also as-
sociated with even more severe hippocampal atrophy on
MRI as seen in AD [25,30,67,91]. In addition, the com-
plexity of disorders should be kept in mind when recruit-
ing demented patients for genome-wide studies.
Theoretically, modifications of the most relevant pro-
teins (Aβ, tau, α-synuclein, TDP-43) would be pivotal for
evaluation simultaneously with different methods [2].
This technique should complement the detection ofbiomarkers associated with pathogenetic processes, and
also neuroimaging and genetic analysis, in order to ob-
tain a highly personalized diagnostic profile [2]. This
concept emphasizes the continuous need for clinical–
radiological–neuropathological studies to define new
clusters of patients with cognitive decline, which might
be useful for monitoring therapy and may open new ave-
nues for research on pathogenesis.
Neuropathological studies should use a wide range of
molecular pathological methods and should evaluate many
brain regions. In addition to careful mapping of vascular
lesions and histological signs of non-neurodegenerative
disorders, immunostaining for p62/ubiquitin (that is,
markers indicating alteration in the ubiquitin–proteasome
system) may be used to screen for neurodegenerative
pathology. An optimal, but less cost-effective, strategy
would be to screen specifically for neurodegeneration-
related proteins [3]. Strategic blocks for p62/ubiquitin im-
munohistochemical screening should include the hippo-
campus, amygdala, basal ganglia, and medulla oblongata.
Screening for neurodegeneration-related proteins may in-
clude the hippocampus (that is, tau, TDP-43), the basal
ganglia (that is, tau, TDP-43, Aβ), amygdala (that is, tau,
TDP-43, α-synuclein), mesencephalon and medulla oblon-
gata (that is, α-synuclein), and neocortical areas (that is,
frontal, temporal for Aβ). When immunoreactivity for any
protein is detected in these regions, full mapping, follow-
ing diagnostic staging or classification systems is war-
ranted. Even if the costs are higher for this strategy,
omitting this concept can lead to considerable delays in
the understanding of the spectrum and implications of
brain pathologies in older people.
Finally, at least in the older population, targeting only
single proteins for therapy might offer less success; com-
bined preventive measures that increase the efficiency of
the protein processing systems and aim to decrease vas-
cular risk factors could be also considered.Abbreviations
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